MBX Biosciences, Inc. (MBX)
Develops peptide drugs to treat hormone and metabolic disorders like low calcium and obesity.
$59.14-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+330.1%
The outlook
MBX is trading near recent highs, comfortably above its key moving averages. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and their average price target sits about 30% above the current level. The overall technical and sentiment picture leans decidedly bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +30% vs current price
Analyst price target
~12-month · 10 analysts$77.00average target+30.2% vs now
Now $59.14
Low $56.00High $91.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.81B
52-wk high
$66.66
52-wk low
$9.63
50-day avg
$45.33
200-day avg
$33.98
Trailing P/E
—